Sepsis is a serious global health issue, with septic shock carrying a high mortality rate (~38.5%). The optimal blood pressure target for managing septic shock remains unclear. Recent trials show...
READ MORE
The growing integration of digital technologies in the National Health Service (NHS) has enabled the transformation of traditional clinical protocols into digital tools, with sepsis screeni
READ MORE
Sepsis and septic shock represent critical conditions frequently encountered in emergency medicine, carrying significant risks of morbidity and mortality. Vitamin C has been proposed as a potential...
READ MORE
Sepsis remains a major cause of illness and death among children worldwide. Although mortality has decreased due to quality improvement initiatives and clinical guidelines, 4–10% of paediatric sepsis
READ MORE
Sepsis remains a major global health issue, with nearly 49 million cases and 11 million deaths annually. International guidelines emphasise routine screening and standardised treatment protocols...
READ MORE
Sepsis is a major cause of death and disability. The Centers for Medicare & Medicaid Services (CMS) aims to improve sepsis outcomes through the Severe Sepsis and Septic Shock Management Bundle (S
READ MORE
Pancreatic stone protein (PSP), C-reactive protein (CRP), and procalcitonin (PCT) are potential biomarkers for early detection of infection and sepsis in critically ill patients. A
READ MORE
The complexity of clinical trials in critical illness remains a significant challenge. A discussion at the ISICEM Congress in Brussels focused on why trials often fail, the role of heteroge
READ MORE
Sepsis is a common and potentially fatal condition, causing over 270,000 deaths annually in the U.S. Emergency treatment involves fluids and vasopressors, with norepinephrine as the first-line choice
READ MORE
Early recognition and treatment of sepsis are crucial for improving patient outcomes, leading to clinical guidelines recommending sepsis screening programmes. However, evidence supporting these progr
READ MORE
